Quanterix Reported Q4 Revenue Of $34.9M, Up 11% YoY, Cash Balance Of 44.4M

Benzinga
01-14

Selected Preliminary, Unaudited Fourth Quarter 2024 Financial Results

  • Revenue of approximately $34.9 million for the three months ended December 31, 2024, representing 11% year-over-year growth.
    • Instruments revenue of approximately $3.1 million, representing a 6% year-over-year decline.
    • Consumables revenue of approximately $17.4 million, remaining flat year-over-year.
    • Accelerator revenue of approximately $8.6 million, representing 22% year-over-year growth. As previously disclosed, the fourth quarter performance does not include $1.5 million of revenue from an order under an agreement with Eli Lilly, which was completed in the third quarter of 2024.
    • Other revenue of approximately $5.8 million, representing 57% year-over-year growth.
  • The Company used approximately $4.4 million of cash in the quarter ended December 31, 2024.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10